Omniabio

Overview

OmniaBio is a specialized contract development and manufacturing organization (CDMO) focused exclusively on cell and gene therapy (CGT). The company partners with biotech innovators to advance autologous and allogeneic cell therapies, lentiviral vector (LVV) platforms, and induced pluripotent stem cell (iPSC)-based programs from preclinical development through commercial-scale manufacturing.

Core Services

• Process Development & Optimization: Expertise in developing and optimizing manufacturing platforms with enhanced robustness and reliable scale-up capabilities.
• Analytical Development: Comprehensive analytical development services for tailored and established assays.
• GMP Manufacturing: Resilient and scalable manufacturing with Grade B or Grade C GMP suite options compliant with U.S., Canadian, and European regulations.
• Cell Banking: Dedicated cell banking services supporting therapeutic programs.
• Regulatory Guidance: CMC program support and regulatory pathway navigation.
• Supply Chain Security: End-to-end supply chain oversight.

Technology & Infrastructure

OmniaBio operates Canada's largest CGT manufacturing facility (120,000 sq ft) in Hamilton, Ontario. The facility integrates:

• Hamilton Intelligent Facility: AI and robotics integration for enhanced production rates and reduced manufacturing costs.
• Closed-unit systems: Automated, closed manufacturing platforms for consistency and risk mitigation.
• Advanced cell platforms: Purpose-built infrastructure for lentiviral vector, immune cell, and iPSC-based therapies.

Differentiation

The company emphasizes phase-appropriate services, collaborative partnerships, and a focus on reducing risk and amplifying assurance. With over a decade of collective experience in immune cell-based therapy process development, OmniaBio positions itself as both a manufacturing partner and an innovation collaborator, supporting clients from early development through commercial supply.